Soluble CLEC-2 Ratio Biomarker for Platelet Activation Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for measuring platelet activation, such as using PF4, β-thromboglobulin, and membrane glycoproteins, are unreliable due to non-specific release during blood collection and lack clinical significance, while soluble CLEC-2 alone does not accurately reflect platelet activation status due to correlation with platelet count variations.
Innovation Solution
Measure the concentration of soluble CLEC-2 and platelet count, calculate the ratio [soluble CLEC-2 concentration]/[platelet count], and compare it with healthy individuals to accurately assess platelet activation and thrombotic hemostatic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If soluble CLEC-2 concentration is used as a platelet activation marker, then platelet activation can be detected, but the measurement is affected by platelet count variations leading to inaccurate assessment
Solution Approach 1:
The invention changes the measurement parameter from absolute soluble CLEC-2 concentration to a normalized ratio (soluble CLEC-2 concentration/platelet count). This parameter transformation eliminates the confounding effect of platelet count variations, allowing accurate assessment of platelet activation independent of platelet number changes.
2Measurement precision
If conventional markers like PF4 or β-thromboglobulin are used, then platelet activation can be detected, but complicated blood collection procedures are required
Solution Approach 1:
The invention extracts and utilizes soluble CLEC-2, a marker that is naturally released into plasma during platelet activation, unlike granule contents that require special handling. This extraction of a suitable biomarker enables detection of platelet activation using routine blood collection procedures without requiring specialized tubes or immediate processing.
3Measurement precision
If membrane glycoproteins like GPIba or GPVI are used as markers, then platelet activation can be detected, but clinical significance is unclear due to ligand-dependent release
Solution Approach 1:
The invention utilizes soluble CLEC-2, a stable protein marker released during platelet activation, replacing unstable or ligand-dependent markers like cleaved membrane glycoproteins. This disposable-like approach uses a robust, easily measurable marker that provides reliable clinical information without the complexities of ligand-dependent release mechanisms.
Data Source
AI summary
Provided is a method for assisting in grasping the status of platelet activation, by developing a biomarker that more accurately reflects platelet activation in vivo, said method being usable in testing for thrombotic hemostatic diseases. The method for assisting in grasping the status of platelet activation comprises (1) measuring the concentration of soluble CLEC-2 and a platelet count in a sample obtained from a subject, and (2) calculating a value of [soluble CLEC-2 concentration]/[platelet count] by dividing the soluble CLEC-2 concentration by the platelet count. If desired, the method may further comprise (3) comparing the value with a value of [soluble CLEC-2 concentration]/[platelet count] obtained by using samples from healthy persons.